About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Expert Opinion on Drug Safety
›
top-articles
Expert Opinion on Drug Safety
2.7
(top 20%)
impact factor
2.2K
(top 10%)
papers
55.8K
(top 5%)
citations
93
(top 5%)
h
-index
2.9
(top 20%)
impact factor
2.6K
all documents
59.4K
doc citations
140
(top 5%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Clinical consequences of polypharmacy in elderly
Expert Opinion on Drug Safety
2014
1,217
2
DPP-4 inhibitors: pharmacological differences and their clinical implications
Expert Opinion on Drug Safety
2014
588
3
Long-term side effects of glucocorticoids
Expert Opinion on Drug Safety
2016
479
4
Safety of aerosolized amphotericin B
Expert Opinion on Drug Safety
2007
478
5
Paclitaxel: a review of adverse toxicities and novel delivery strategies
Expert Opinion on Drug Safety
2007
388
6
An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease
Expert Opinion on Drug Safety
2016
306
7
An update on the clinical consequences of polypharmacy in older adults: a narrative review
Expert Opinion on Drug Safety
2018
299
8
Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis
Expert Opinion on Drug Safety
2014
260
9
Adverse reactions to first-line antituberculosis drugs
Expert Opinion on Drug Safety
2006
256
10
A review of the efficacy and safety of oral antidiabetic drugs
Expert Opinion on Drug Safety
2013
251
11
A systematic review of the safety of probiotics
Expert Opinion on Drug Safety
2014
250
12
Statin-induced myopathy: a review and update
Expert Opinion on Drug Safety
2011
248
13
A review of existing and emerging digital technologies to combat the global trade in fake medicines
Expert Opinion on Drug Safety
2017
238
14
Hydroxychloroquine in systemic lupus erythematosus (SLE)
Expert Opinion on Drug Safety
2017
236
15
Statin use and cancer risk: a comprehensive review
Expert Opinion on Drug Safety
2010
235
16
Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis
Expert Opinion on Drug Safety
2016
235
17
Fluoropyrimidine-associated cardiotoxicity: revisited
Expert Opinion on Drug Safety
2009
220
18
Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity
Expert Opinion on Drug Safety
2005
216
19
Drug-induced phospholipidosis: issues and future directions
Expert Opinion on Drug Safety
2006
216
20
The role of data mining in pharmacovigilance
Expert Opinion on Drug Safety
2005
211
21
Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine
Expert Opinion on Drug Safety
2014
209
22
Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety
Expert Opinion on Drug Safety
2006
205
23
Renal adverse effects of nonsteroidal anti-inflammatory drugs
Expert Opinion on Drug Safety
2009
203
24
The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms
Expert Opinion on Drug Safety
2006
198
25
Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions
Expert Opinion on Drug Safety
2012
192
26
Thiazolidinedione safety
Expert Opinion on Drug Safety
2012
175
27
Teratogenicity of sodium valproate
Expert Opinion on Drug Safety
2005
172
28
Adverse events associated with mTOR inhibitors
Expert Opinion on Drug Safety
2013
172
29
Safety profile of tasimelteon, a melatonin MT
1
and MT
2
receptor agonist: pooled safety analyses from six clinical studies
Expert Opinion on Drug Safety
2015
172
30
Hydroxyurea therapy for sickle cell anemia
Expert Opinion on Drug Safety
2015
172
31
Safety of benzodiazepines in the geriatric population
Expert Opinion on Drug Safety
2004
171
32
Pioglitazone: side effect and safety profile
Expert Opinion on Drug Safety
2010
170
33
Safety profile of iloperidone in the treatment of schizophrenia
Expert Opinion on Drug Safety
2014
165
34
Safety and tolerability of antipsychotic polypharmacy
Expert Opinion on Drug Safety
2012
163
35
Anti-obesity drugs: a review about their effects and their safety
Expert Opinion on Drug Safety
2012
162
36
Anthracycline cardiotoxicity
Expert Opinion on Drug Safety
2012
161
37
Idiosyncratic drug-induced liver injury: an overview
Expert Opinion on Drug Safety
2007
158
38
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Expert Opinion on Drug Safety
2017
156
39
The potential adverse effects of habitual use ofCatha edulis(khat)
Expert Opinion on Drug Safety
2005
155
40
Weight gain and antipsychotics: a drug safety review
Expert Opinion on Drug Safety
2015
155
41
Infection risk associated with anti-TNF-α agents: a review
Expert Opinion on Drug Safety
2015
153
42
Revisiting doxycycline in pregnancy and early childhood – time to rebuild its reputation?
Expert Opinion on Drug Safety
2016
146
43
Drug-induced serotonin syndrome: a review
Expert Opinion on Drug Safety
2008
145
44
Naloxone treatment in opioid addiction: the risks and benefits
Expert Opinion on Drug Safety
2007
141
45
The side effects of the prostaglandin analogues
Expert Opinion on Drug Safety
2007
141
46
How safe is the use of thiazolidinediones in clinical practice?
Expert Opinion on Drug Safety
2009
136
47
Drugs with anticholinergic properties: a current perspective on use and safety
Expert Opinion on Drug Safety
2011
136
48
Adalimumab: a review of side effects
Expert Opinion on Drug Safety
2005
131
49
Everolimus and sirolimus in transplantation-related but different
Expert Opinion on Drug Safety
2015
131
50
Reactivation of hepatitis B virus with rituximab
Expert Opinion on Drug Safety
2005
130
site/software ©
exaly
; All materials licenced under
CC by-SA
.